Personalis SEC Filings

Personalis, Inc. director Olivia Kyusuk Bloom reported equity compensation awards consisting of restricted stock units (RSUs) and stock options. She received 6,250 RSUs, each representing one share of common stock upon settlement, and 37,500 stock options with an exercise price of $6.04 per share. The filing states that 100% of both the RSUs and options vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the day prior to the company’s next annual meeting of stockholders, subject to her continuous service under the 2019 Equity Incentive Plan. In the event of a Change in Control, the RSUs and options vest immediately before that transaction becomes effective. After the RSU grant, Bloom directly owns 27,265 shares of common stock.

Personalis, Inc. director Woodrow A. Myers Jr. received equity compensation in the form of restricted stock units and stock options. He was granted 6,250 RSUs, each representing one share of common stock, bringing his direct common stock holdings to 32,366 shares after the award.

He was also granted options covering 37,500 shares of common stock at an exercise price of $6.04 per share, expiring on May 12, 2036. Both the RSUs and options vest 100% on the earlier of one year from the grant date or the day before the next annual stockholder meeting, with accelerated vesting immediately before a qualifying Change in Control if he remains in Continuous Service.

Personalis, Inc. reported the results of its 2026 annual meeting of stockholders. Shareholders representing 91,869,300 shares, or 87.76% of the 104,677,900 shares outstanding as of March 17, 2026, were present, establishing a quorum to conduct business.

Two Class I directors, Olivia K. Bloom and Woodrow A. Myers, Jr., M.D., were elected to serve until the 2029 annual meeting, with 75,695,538 and 68,240,509 votes cast in their favor, respectively. Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with 91,586,300 votes for. In an advisory vote, stockholders approved the compensation of the company’s named executive officers, with 75,549,455 votes for and relatively few votes against or abstentions.

Personalis, Inc. reported that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has expanded Medicare coverage for its ultrasensitive NeXT Personal® test. The expansion now includes use of the test for immunotherapy monitoring in patients with late-stage solid tumors.

This change means NeXT Personal can be covered by Medicare when used to track how late-stage solid tumor patients respond to immunotherapy, potentially broadening clinical use within the Medicare population.

Personalis, Inc. ownership disclosure: Deep Track entities and David Kroin report beneficial ownership of 5,760,627 shares of common stock, representing 5.51% of the class. The filing states this position is held with shared voting and shared dispositive power as of May 12, 2026.

The filing identifies Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin as reporting persons and cites 104,631,832 shares outstanding as of February 20, 2026 for the percent calculation. The filing is a joint Schedule 13G disclosure under applicable ownership rules.

Personalis, Inc. has filed a shelf registration and prospectus to offer and sell up to $150,000,000 of its common stock from time to time under an amended and restated at-the-market sales agreement with Piper Sandler & Co. and BTIG, LLC. Sales may occur on a continuous or delayed basis on the Nasdaq Global Market under the symbol PSNL.

The offering is structured as an at-the-market program and the Sales Agents may sell shares on our behalf for up to the aggregate offering price stated above; the Sales Agents may receive commissions up to 3.00% of gross proceeds.

Personalis, Inc. reported first-quarter 2026 revenue of $15.5 million, down 25% from $20.6 million a year earlier, as pharma testing, enterprise sales, and population sequencing all declined. Enterprise revenue dropped sharply as work with Natera wound down, while VA population sequencing revenue also fell.

Clinical diagnostic revenue rose to $1.4 million from $0.3 million, helped by new Medicare coverage decisions for NeXT Personal Dx in breast cancer and non-small cell lung cancer. Total costs and expenses increased to $47.6 million, leading to a net loss of $30.0 million, compared with a $15.8 million loss a year earlier.

Personalis ended March 31, 2026 with $233.2 million in cash, cash equivalents, and short-term investments and $0.9 million of debt. Operating activities used $22.5 million of cash in the quarter, and the company raised $21.0 million via at-the-market common stock sales.

Personalis, Inc. reported first quarter 2026 revenue of $15.5 million, down from $20.6 million a year earlier as non-core revenue declined while the company shifted focus to its minimal residual disease (MRD) offering. The net loss widened to $30.0 million, compared with $15.8 million in the prior-year quarter, as operating expenses increased.

Clinical test revenue rose to $1.4 million from $0.3 million, with clinical test volume surging 258% year-over-year to 7,815 tests, helped by growth in the NeXT Personal MRD test. Personalis secured Medicare coverage for lung cancer surveillance, adding to existing breast cancer coverage, and ended the quarter with about $233.2 million in cash, cash equivalents and short-term investments.

The company reaffirmed its full-year 2026 outlook, including total revenue of $78.0–$80.0 million, clinical test volume of 43,000–45,000 tests, clinical revenue of $10.0–$11.0 million, gross margin of 15%–20%, a net loss of about $105.0 million, and projected cash usage of about $100.0 million.

PERSONALIS INC filing reports that T. Rowe Price Investment Management, Inc. beneficially owns 4,758,091 shares of Common Stock, representing 4.5% of the class. The filing states all voting and dispositive power is sole rather than shared. The signature is dated 04/08/2026.